AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$LGND

Reardon Andrew sold $1.5M of LGND

Reardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $304.07 ($302.51–$307.74, $1.52M total) across 6 trades on 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reardon Andrew
Published Oct 6, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LGND
Bearish
high confidence
Mentioned
$LGND
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LGNDBearishLow
01

Why it matters

The disclosed sale provides fresh data for traders assessing LGND's short‑term outlook.

02

Market read

Primary insider sale; modest materiality but new information for market participants.

03

What to watch

The 10b5-1 plan may have been set months ago; the timing may not reflect current sentiment.

Relevance 5/10Novelty 7/10Timing: after-hours today

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$LGNDBearishHigh confidence
Context

Officer and Secretary Reardon Andrew sold 5,000 shares for $1.5M via a 10b5-1 plan, reducing his stake to 31,854 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $1.5M sale by a senior officer is a material new filing; traders often view such sales as bearish.

Market effects

Sector

Minimal impact on the broader biotech sector; the sale is company‑specific.

Regional

No significant regional effect; limited to LGND shareholders.

Global

Low global relevance; only relevant to investors in LGND.

Counterpoint

What could challenge this read

The sale could be routine execution of a pre‑arranged plan, not a signal of trouble.

Key entities

  • Company
    Ligand Pharmaceuticals Inc.

    Biotech firm listed on NASDAQ under LGND.

  • Insider
    Reardon Andrew

    Chief Legal Officer and Secretary of Ligand Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LGND insider trading history →

Related articles

SEP 27
$LGNDMed

Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones

Ligand Pharmaceuticals (LGND) announced a $47M financing deal with AvenCell Therapeutics, including $6M for Series C funding and $41M for drug development, tied to milestones. Ligand aims for mid-single-digit to low-double-digit royalties on AvenCell's sales. The company's royalty revenue grew 32% YoY to $48M in Q2, with a target of $225M-$250M for 2026. Ligand has $1.36B in cash and $700M for further investments.

insidermonkey.com2 min
SEP 24
$LGNDMed

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., September 24, 2026 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a f

SEC EDGAR 8-K1 min
SEP 4
$LGNDHighAI 8/10

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.

insidermonkey.com3 min
AUG 13
$LGNDHighAI 9/10

Ligand (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.

fool.com6 min
AUG 8
$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min